Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
蛋白别名: Cancerous inhibitor of PP2A; cancerous inhibitor of protein phosphatase 2A; p90 autoantigen; p90 autoantigen homolog; Protein CIP2A; similar to RIKEN cDNA C330027C09
基因别名: AA408511; AU018569; CIP2A; KIAA1524; p90
UniProt ID: (Mouse) Q8BWY9, (Human) Q8TCG1
Entrez Gene ID: (Mouse) 224171, (Human) 57650, (Rat) 360711
